Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method

Vaccine

Volumn 28, Issue 31, 2010, Pages 5093-5099

  Chen, D ^a   Kapre, S ^b   Goel, A ^b   Suresh, K ^b   Beri, S ^b   Hickling, J ^c   Jensen, J ^d   Lal, M ^a   Preaud, J M ^a   LaForce, M ^a   Kristensen, D ^a  

^a PATH   (United States)

^b Serum Institute of India Ltd   (India)

^c Working in Tandem Ltd   (United Kingdom)

^d NONE

Author keywords

Formulation; Spray dry; Stability; Vaccine

Indexed keywords

BACTERIAL PROTEIN; HEPATITIS B VACCINE; MENINGITIS VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT HEPATITIS B VACCINE; ALUMINUM DERIVATIVE; BACTERIAL VACCINE; IMMUNOLOGICAL ADJUVANT; POLYSACCHARIDE; POWDER; SUBUNIT VACCINE; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; HEPATITIS B; INFECTION PREVENTION; MENINGITIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SPRAY DRYING; THERMOSTABILITY; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DESICCATION; DRUG STABILITY; HEPATITIS B VIRUS; IMMUNOLOGY; PHARMACOLOGY; PILOT STUDY; POWDER; TEMPERATURE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; BACTERIAL VACCINES; DESICCATION; DRUG STABILITY; HEPATITIS B VACCINES; HEPATITIS B VIRUS; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP A; PILOT PROJECTS; POLYSACCHARIDES; POWDERS; TEMPERATURE; VACCINES, CONJUGATE; VACCINES, SUBUNIT;

EID: 77954760487     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.112     Document Type: Article

References (26)

1. Setia S., Mainzer H., Washington M.L., Snyder R., Weniger B.G. Frequency and causes of vaccine wastage. Vaccine 2002, 20(7-8):1148-1156.
2. Techathawat S., Varinsathien P., Rasdjarmrearnsook A., Tharmaphornpilas P. Exposure to heat and freezing in the vaccine cold chain in Thailand. Vaccine 2007, 25(7):1328-1333.
3. Matthias D.M., Robertson J., Garrison M.M., Newland S., Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 2007, 25(20):3980-3986.
4. Levin A., Levin C., Kristensen D., Matthias D. An economic evaluation of thermostable vaccines in Cambodia, Ghana, and Bangladesh. Vaccine 2007, 25(39-40):6945-6957.
5. Burke C.J., Hsu T.A., Volkin D.B. Formulation, stability, and delivery of live-attenuated vaccines for human use. Crit Rev Ther Drug Carrier Syst 1999, 16(1):1-83.
6. Pisal S., Wawde G., Salvankar S., Lade S., Kadam S. Vacuum foam drying for preservation of LaSota virus: effect of additives. AAPS PharmSciTech 2006, 7(3):60.
7. Wong Y.L., Sampson S., Germishuizen W.A., Goonesekera S., Caponetti G., Sadoff J., et al. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci USA 2007, 104(8):2591-2595.
8. Maa Y.F., Ameri M., Shu C., Payne L.G., Chen D. Influenza vaccine powder formulation development: spray-freeze drying and stability evaluation. J Pharm Sci 2004, 93(7):1912-1923.
9. Amorij J., Meulenaar J., Hinrichs W.L.J., Stegmann T., Huckriede A., Coenen, et al. Rational design of an influenza subunit vaccine powder with sugar-glass technology: preventing conformational changes of haemagglutinin during freezing and freeze drying. Vaccine 2007, 25(35):6447-6457.
10. Burger J.L., Cape S.P., Braun C.S., McAdams D.H., Best J.A., Bhagwat P., et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 2008, 21(1):25-34.
11. Kling J. Inhaled insulin's last gasp?. Nat Biotechnol 2008, 26(5):479-480.
12. Bosquillon C., Rouxhet P.G., Ahimou F., Simon D., Culot C., Préat V., et al. Aerosolization properties, surface composition, and physical state of spray-dried protein powders. J Control Release 2004, 99(3):357-367.
13. Kaushik J.K., Bhat R. Why is trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolyte trehalose. J Biol Chem 2003, 278(29):26458-26465.
14. Cicerone M.T., Soles C.L. Fast dynamics and stabilization of proteins: binary glasses of trehalose and glycerol. Biophys J 2004, 86(6):3836-3845.
15. Crowe J.H., Crowe L.M., Oliver A.E., Tsvetkova N., Wolkers W., Tablin F. The trehalose myth revisited: introduction to a symposium on stabilization of cells in the dry state. Cryobiology 2001, 43(2):89-105.
16. Lee C., Kuo W., Beri S., Kapre S., Joshi J.S., Bouveret N., et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009, 27(5):726-732.
17. Chen D., Tyagi A., Carpenter J., Perkins S., Sylvester D., Guy M., et al. Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccine 2009, 5(1):26-32.
18. Maa Y., Zhao L., Payne L., Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 2003, 92(2):319-332.
19. Jezek J., Chen D., Watson L., Crawford J., Perkins S., Tyagi A., et al. A heat-stable hepatitis B vaccine formulation. Hum Vaccine 2009, 5(8):529-535.
20. Chen D., Kristensen D. Opportunities and challenges of developing thermostable vaccines. Exp Rev Vaccines 2009, 8(5):547-557.
21. Milstien J.B., Galazka A.M., Kartoglu Ü, Zaffran M. The temperature sensitivity of vaccines 2006, The World Health Organization, Geneva.
22. Braun L.J., Jezek J., Peterson S., Tyagi A., Perkins S., Sylvester D., et al. Characterization of a thermostable hepatitis B vaccine formulation. Vaccine 2009, 27(34):4609-4614.
23. Corbanie E.A., Remon J.P., Van Reeth K., Landman W.J., van Eck J.H., Vervaet C. Spray drying of an attenuated live Newcastle disease vaccine virus intended for respiratory mass vaccination of poultry. Vaccine 2007, 25(49):8306-8317.
24. Hipgrave D.B., Maynard J.E., Biggs B.A. Improving birth-dose coverage of hepatitis B vaccine. Bull World Health Organ 2006, 84(1):65-71.
25. Jódar L., LaForce F.M., Ceccarini C., Aguado T., Granoff D.M. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003, 361(9372):1902-1904.
26. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Préziosi M.P., et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007, 25(Suppl 1):A101-A107.